Qualitative Concept
FDA Approves Novocure’s Optune Lua for Metastatic Non-Small Cell Lung Cancer Treatment
Optune Lua, FDA approval, metastatic non-small cell lung cancer, Tumor Treating Fields, Novocure, NSCLC treatment.
Novocure’s Optune Lua Wins FDA Approval for Metastatic Non-Small Cell Lung Cancer Treatment
Novocure, Optune Lua, FDA approval, metastatic non-small cell lung cancer, TTFields, lung cancer treatment, PD-1/PD-L1 inhibitors, docetaxel.
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Compounding
Tirzepatide, FDA, drug shortage, compounding pharmacies, GLP-1 medications
HIV Prevention: A Proven Solution Eludes Many Due to Systemic Barriers
HIV Prevention, PrEP (Pre-Exposure Prophylaxis), Health Equity, Marginalized Communities, Stigma, Access to Healthcare
Tolerance Bio Secures $17.2M Seed Funding to Develop Thymus-Targeted Cell Therapies
Tolerance Bio, cell therapy, thymus, immune-mediated diseases, seed funding, allogeneic iPSC-based therapy
FDA Approves CMR Surgical’s Versius Robot for Cholecystectomies in Adults
CMR Surgical, Versius Surgical System, FDA Approval, Cholecystectomies, Robotic-Assisted Surgery
Pfizer’s HYMPAVZI Receives FDA Approval for Hemophilia A and B Treatment
HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Access to Compounded Versions
FDA, tirzepatide, drug shortage, compounded medications, Eli Lilly, type 2 diabetes, weight loss, GLP-1 medications
FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies
FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment
Pfizer Secures Second FDA Approval for Hemophilia Treatment in Six Months
Pfizer, FDA approval, Hemophilia, Gene Therapy, Hemophilia B, HYMPAVZI